Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
122 hedge funds and large institutions have $253M invested in Keryx Biopharmaceuticals Inc in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 42 reducing their positions, and 22 closing their positions.
0.8% less ownership
Funds ownership: 62.53% → 61.74% (-0.8%)
7% less funds holding
Funds holding: 131 → 122 (-9)
11% less capital invested
Capital invested by funds: $283M → $253M (-$30.2M)
24% less call options, than puts
Call options by funds: $1.1M | Put options by funds: $1.46M
26% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 42
41% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$3.68M |
| 2 |
BlackRock
New York
|
+$2.11M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.07M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.17M |
| 5 |
Citigroup
New York
|
+$773K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
-$5.48M |
| 2 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
-$3.03M |
| 3 |
Morgan Stanley
New York
|
-$2.69M |
| 4 |
RA
Royce & Associates
New York
|
-$965K |
| 5 |
CEP
Chicago Equity Partners
Chicago,
Illinois
|
-$747K |
KERX Hedge Fund Activity: Q3 2018 in Review
122 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q3 2018, worth a combined $253M — down 11% from $283M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of KERX and 13 opened new positions — a net loss of 9 holders — while 42 trimmed existing stakes and 31 added.
The largest buyer was State Street, adding an estimated $3.68M. The largest seller was ClearBridge LLC (Maryland), exiting entirely with an estimated $5.48M sold.
- 122 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q3 2018, down from 131 in Q2 2018.
- Funds reported $253M of Keryx Biopharmaceuticals Inc stock for Q3 2018, down 11% quarter-over-quarter.
- 13 funds opened new Keryx Biopharmaceuticals Inc positions in Q3 2018 and 22 closed out, a net change of -9 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q3 2018 was State Street, an estimated $3.68M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q3 2018 was ClearBridge LLC (Maryland), an estimated $5.48M sold.
Based on aggregated 13F filings for Q3 2018.